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Sulayman D. 11, 12 Itch is thought to represent the peculiar response to stimuli conveyed by somatosensory pathways shared with pain through the activation of specific neurons and receptors. It can occur in association with dermatological, systemic and neurological diseases, or be the side effect of certain drugs. However, some patients suffer from chronic idiopathic itch that is frequently ascribed to psychological distress and for which no biomarker is available to date. We investigated three multigenerational families, one of which diagnosed with joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type (JHS/EDS-HT), characterized by idiopathic chronic itch with predominantly proximal distribution. Skin biopsy was performed in all eight affected members and revealed in six of them reduced intraepidermal nerve fibre density consistent with small fibre neuropathy. Whole exome sequencing identified two COL6A5 rare variants co-segregating with chronic itch in eight affected members and absent in non-affected members, and in one unrelated sporadic patient with type 1 painless diabetic neuropathy and chronic itch. Two families and the diabetic patient carried the nonsense c.6814G4T (p.Glu2272 * ) variant and another family carried the missense c.6486G4C (p.Arg2162Ser) variant. Both variants were predicted as likely pathogenic by in silico analyses. The two variants were rare (minor allele frequency 5 0.1%) in 6271 healthy controls and absent in 77 small fibre neuropathy and 167 JHS/EDS-HT patients without itch. Null-allele test on cDNA from patients' fibroblasts of both families carrying the nonsense variant demonstrated functional haploinsufficiency due to activation of nonsense mediated RNA decay. Immunofluorescence microscopy and western blotting revealed marked disorganization and reduced COL6A5 synthesis, respectively. Indirect immunofluorescence showed reduced COL6A5 expression in the skin of patients carrying the nonsense variant. Treatment with gabapentinoids provided satisfactory itch relief in the patients carrying the mutations. Our findings first revealed an association between COL6A5 gene and familiar chronic itch, suggesting a new contributor to the pathogenesis of neuropathic itch and identifying a new candidate therapeutic target.
Introduction
Itch is a common experience of unbearable cutaneous discomfort with the urgent need to scratch for immediate relief, and has different causes including allergies, insect bite or the scar of a healing wound. Itch can complicate the course of a wide range of systemic illnesses such as atopic dermatitis, psoriasis, parasitosis, varicella, myeloproliferative malignancies, cholestasis, Graves' disease, iron-deficiency anaemia and diabetes mellitus (Yosipovitch and Bernhard, 2013) . It can also occur in peripheral and central nervous system diseases such as post-herpetic neuralgia, neuropathies, inflammatory and vascular lesions of the thalamus, brainstem or spinal cord, dementia and Creutzfeldt-Jakob disease (Dhand and Aminoff, 2014; Misery et al., 2014) . Furthermore, itch can be a side effect of drugs like opioids and chloroquine (Reich et al., 2009) . However, some patients complain of chronic itch of unknown aetiology, which can be related to psychological distress, especially in the elderly (Yosipovitch and Bernhard, 2013; Dhand and Aminoff, 2014) and their response to anti-histaminergic drugs is typically poor (Yosipovitch and Bernhard, 2013) .
The neurobiology of itch has been partly elucidated by the discovery of subsets of sensory neurons that specifically respond to pruritic stimuli such as histamine, cowhage, chloroquine, and opiates (Liu et al., 2009; Han et al., 2013; Roberson et al., 2013) . These neurons are recognized by the expression of various membrane receptors (Ikoma et al., 2006; LaMotte et al., 2014) , which explain a differing response to nociceptive and pruritic stimuli (LaMotte et al., 2014) through the activation of subsets of peripheral receptors in the skin and the modulation of various neurotransmitters in the spinal cord (Namer et al., 2008) . For example, unmyelinated mechano-insensitive nerve fibres contribute to the response to histamine (Schley et al., 2013) , while both unmyelinated mechano-sensitive and thinly myelinated nerve fibres play a role in non-histamine mediated itch, like that induced by cowhage (Ringkamp et al., 2011) .
Peripheral sensory nerve fibres arise from dorsal root ganglion (DRG) neurons that specialize during development to contribute to different sensory modalities (Lallemend and Ernfors, 2012) . This is a process regulated by transcription factors that determine the specialization for thermal, nociceptive and itch perceptions (Liu and Ma, 2011; Hadjab et al., 2013; Yang et al., 2013) . Pruriceptor neurons identified thus far represent $5% of the DRG population that are recognized by the expression of MRGPRA3, and they selectively innervate the epidermis, explaining why itch is perceived on the superficial skin (Liu et al., 2009; Han et al., 2013) . Keratinocytes may also contribute to itch through the activation of chemosensitive receptors and mediators that can activate pruriceptor neurons (Wilson et al., 2013) .
However, little is known about spontaneous itch. Experimental models have suggested that silencing of genes encoding for the vesicular glutamate transporter 2 (VGLUT2) (Lagerstrom et al., 2010; Liu et al., 2010) , transient receptor potential vanilloid type 1 (TRPV1), and transient receptor potential cation channel ankyrin 1 (TRPA1) (Roberson et al., 2013) in sensory neurons or the lack of inhibitory interneurons expressing the transcription factor basic helix-loop-helix domain-containing class B5 (BHLHB5, now known as BHLHE22) (Ross et al., 2010) can result in spontaneous itch. To date, no molecular markers have been identified in patients with idiopathic spontaneous itch, which hinders the development of targeted therapeutic strategies.
Here we describe the first gene variants identified in eight patients from three kindred and one sporadic patient, all suffering from idiopathic chronic itch. Our findings suggest a new contributor to the pathogenesis of itch, which may identify new therapeutic targets.
Patients and methods

Family 1
The proband was a 38-year-old male complaining of spontaneous chronic itch for $5 years. Itch involved mainly the proximal upper limbs and trunk, with daily episodes of fluctuating intensity lasting 30-60 min. The patient could not identify a trigger for the itch and did not report other sensory disturbances either during or between attacks. Itch induced the need to scratch, which the patient had learnt to control, at least for the milder attacks. Sleep was not disturbed. His 63-year-old father also complained of spontaneous itch in the same distribution with similar features since he was 30 years old, although the intensity had become more severe in the last few years. His paternal 82-year-old grandmother also complained of a similar itch since the age of 40 years.
The medical history of all the affected family members was otherwise unremarkable. In particular, atopic dermatitis and other dermatological or systemic disorders were ruled out after extensive investigations under dermatology and internal medicine. None were taking any medication known to cause itch; the grandmother was taking an anti-hypertensive treatment. Neurological examination and nerve conduction studies were normal in all patients. The proband and his father underwent spinal cord MRI, which was normal. All patients underwent a 3-mm skin biopsy at the distal site of the leg that showed reduced intraepidermal nerve fibre density (IENFD) in the proband (3.4/mm, 5th percentile 5.2/mm) and his father (2.7/mm, 5th percentile 2.8/mm), but a normal value in the grandmother (5.2/mm, 5th percentile 1.6/mm) (Lauria et al., 2010) . All patients started treatment with gabapentin 900 mg daily and reported a satisfactory relief of the intensity of itch.
Family 2
The proband was a 48-year-old female diagnosed with joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type (JHS/EDS-HT). She complained of chronic spontaneous itch involving the trunk and proximal limbs since the age of 8 years, with daily episodes lasting about 30 min and was frequently of severe intensity. The patient could not identify any trigger for the itch and was taking pregabalin 300 mg daily for the past 5 years to achieve relief from the itch. Since the age of 25 years she also complained of diffuse chronic pain, a known complication of JHS/EDS-HT and was taking oxycodone 40 mg plus naloxone 20 mg daily for this, but did not report any change of itch intensity or frequency after starting opioid treatment.
Her 29-year-old daughter with JHS/EDS-HT also complained of itch with the same features since the age of 5 years. She was taking gabapentin 1200 mg daily, which provided satisfactory itch relief. She also reported diffuse chronic pain not related to the itch attack for which she was not taking any medication. Atopic dermatitis and other dermatological or systemic disorders were ruled out in both patients. Neurological examination, nerve conduction studies, and brain and spinal cord MRI were normal. Skin biopsy at the distal leg showed reduced IENFD both in the proband (4.4/mm, 5th percentile 5.7/mm) and the daughter (2.6/mm, 5th percentile 8.4/mm) (Lauria et al., 2010) .
Family 3
The proband was a 37-year-old female suffering from recurrent daily itch involving the trunk and upper limbs since the age of 15 years (Devigili et al., 2014) . Itch was triggered by environmental warmth, hot drinks, and spicy food, and was followed by a burning sensation and episodic flushing. Her 65-year-old mother also complained of recurrent daily itch attacks and burning with the same features and triggers since she was 54 years old, when she had undergone cardiac ablation for an arrhythmia of unknown origin. Her 42-year-old sister reported recurrent itch followed by a burning sensation and similar triggers since the age of 39 years. The medical history of all affected members was otherwise unremarkable and atopic dermatitis and other dermatological or systemic disorders were ruled out. None of them was taking any medication potentially causing itch. Pregabalin 300 mg daily provided satisfactory itch relief in all patients. Neurological examination revealed tactile hypoaesthesia and hypoalgesia over the shoulders and upper back. Nerve conduction studies and brain and spinal cord MRI were normal. Quantitative sensory testing showed increased thresholds for cold pain, heat pain, and paradoxical heat sensation in all patients with a remarkably identical pattern. Skin biopsy at the distal leg showed reduced IENFD in the proband (3.4/mm; 5th percentile 7.1/mm) and her mother (2.7/ mm, 5th percentile 3.2/mm), but a normal value in the sister (6.8/mm, 5th percentile 5.7/mm) (Lauria et al., 2010) . Cardiovascular autonomic function tests and sympathetic skin response were normal (Heart rate variability, 1996) .
Remarkably, at a 3-year follow-up, the proband's mother (Patient I:2) reported episodic flushing over the face and forearms, warmth intolerance, attacks of hyperhidrosis over the head and thorax, and dry eyes, hands and feet. The sympathetic skin response was absent in the feet and hands. Cardiovascular autonomic function tests (in 1996) showed persistent tachycardia after standing up.
The proband's son (Patient III:1), who was considered as possibly affected at the time of the first examination, did not report itch at 3-year follow-up and does not carry mutations in SCN9A and COL6A5 genes.
Targeted sequence capture and sequencing
Families 1 and 3 were sequenced using the HiSeq 2500 (Illumina). Libraries were prepared using the SureSelect Human All Exon QXT v5 kit (Agilent Technologies) according to manufacturer's protocols and run in pair ended mode (2x101). Size distribution of enriched DNA was checked using the 2100 Bioanalyzer (Agilent Technologies), and concentration measured by Qubit 2.0 Fluorometer (Thermo Fisher). Reads were trimmed using Trimmomatic ver. 0.32 and cutadapt ver. 1.8.3, and aligned with BWA ver. 0.7.10-r789 using hg19 as the reference genome. Variants were identified using GATK ver. 3.3-0-g37228af, annotated using SnpEff suite ver. 4.1 g, and filtered according to the following criteria: (i) depth of called variants (DP 4 6); (ii) predicted to alter protein product (missense were defined as MODERATE impact, and stop-affecting or splice-affecting variants as HIGH impact); (iii) absent in our internal whole-exome sequencing database (n = 60); (iv) minor allele frequency ( Variants found in COL6A5 in the three families were confirmed by Sanger sequencing with BigDye Õ Terminator v1.1
Cycle Sequencing kit on an ABI 3130XL Genetic Analyzer according to manufacturer's protocols (Applied Biosystems).
Skin fibroblasts cultures
Dermal fibroblast cultures from three patients, i.e. Family 1, Patient II:2 and the proband Patient III:1, Family 2, the proband Patient II:4 (Table 1) and two unrelated age-matched healthy donors were established by standard protocols after written informed consent. Dermal fibroblasts were grown in vitro at 37 C in a 5% CO 2 atmosphere in Earle's modified Eagle's medium (MEM) supplemented with 2 mM L-glutamine, 10% foetal bovine serum, 100 mg/ml penicillin and streptomycin (Life Technologies). Fibroblasts were analysed at the same in vitro passage number (from second to fourth) by an observer blinded to the conditions.
Null allele test
To verify the effect of the COL6A5 nonsense variant, total RNA was isolated from patients' skin fibroblasts using the Qiagen RNeasy Õ kit according to the manufacturer's instructions (Qiagen). cDNA synthesis was performed by standard methods using SuperScript TM II reverse transcriptase (Invitrogen) and an exonic primer pair flanking the nonsense mutation, followed by Sanger sequencing of the reverse transcriptase polymerase chain reaction (RT-PCR) product.
Western blotting
Controls' and patients' cultured cells were washed in phosphate-buffered saline and scraped into lysis buffer (20 mM Tris-HCl pH 7.0, 1% Nonidet P-40, 150 mM NaCl, 10% glycerol, 10 mM EDTA, 1 mM phenylmethylsulphonyl fluoride and protease inhibitors). Fifty micrograms of protein were reduced with 10% b-mercaptoethanol and separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis on 4-8% gradient polyacrylamide gel. Fractionated proteins were blotted onto a nitrocellulose membrane at 36 V and the membrane was blocked with 5% dry milk solution overnight at 37 C. Blots were incubated for 3 h with 1 mg/ml rabbit anti-COL6A5 polyclonal antibody (Abcam) or mouse anti-bactin monoclonal antibody (clone AC-74) (Sigma Aldrich), and reactive bands were identified by incubation with 1:1000 horseradish peroxidase-conjugated secondary antibodies and by a chemiluminescent detection method according to the supplier's instructions (Pierce).
Immunofluorescence microscopy
To analyse the expression of COL6A5, immunofluorescence microscopy was performed on 5-day-grown control and patient confluent fibroblasts fixed in cold methanol and immunoreacted with 0.1 mg/ml rabbit anti-COL6A5 polyclonal antibody (Abcam). After washing, cells were reacted with the Alexa Fluor Õ 488 anti-rabbit secondary antibody. Immunofluorescence signals were collected using a CCD black and white TV camera (SensiCam-PCO) mounted on a Zeiss fluorescence-Axiovert microscope and digitalized using the Image-Pro Plus program (Media Cybernetics). Experiments were repeated three times. Quantitative evaluation of fluorescence associated with COL6A5 was performed as previously reported (Zoppi et al., 2004) . Fluorescent images, with the same spatial resolution and comparable light intensity, were captured using the Image-Pro Plus software and a task list file was developed and executed in semi-automatic mode on different images. Each image was processed by applying Sharpen and Rank non-linear filters to optimize image contrast and remove background noise. A binary image, visualized as a red overlay, corresponding to the fluorescence signal, was obtained by setting two thresholds in the fluorescence peak corresponding to the image grey tones visualized, with the lighter tones at the highest value of the peak and the darker ones below the slice background. The sequence of options in the task list was repeated on eighty cells captured randomly on each slide for each sample. The integrated optical density (IOD) related to the cell area containing the signal was measured.
Skin innervation and protein expression
Patients underwent a 3-mm punch skin biopsy at the distal site of the leg following a standardized protocol (Lauria et al., 2010) . Briefly, specimens were fixed (2% paraformaldehydelysine-sodium periodate, 4 C overnight), cryoprotected, serially cut with a cryostat, and immunostained using polyclonal anti-protein gene product 9.5 (Ultraclone Ltd), monoclonal mouse anti-laminin 5 (1:50; EMD Millipore Corporation) and 4',6-diamidino-2-phenylindole (DAPI; 1:10 000, Invitrogen) antibodies. IENFD was calculated on three nonconsecutive central sections by bright-field microscopy using a stereology workstation (Olympus BX50, PlanApo oil-objective 40 Â /NA = 1.0) and compared to sex and age-adjusted normative values (Lauria et al., 2010) . Other sections were used for haematoxylin and eosin staining and S100 protein immunoreactivity. Skin biopsy sections from patients carrying the COL6A5 nonsense variant and two controls were assayed using polyclonal rabbit anti-COL6A5 antibodies (1:200; gift from Prof. R. Wagener). Sections were incubated with 488-conjugated goat anti-rabbit IgG antibody (1:400) and carbocyanine 3 (Cy3)-conjugated donkey anti-mouse IgG antibody (1:400; Jackson Immunoresearch Laboratories) as secondary antibodies.
Images were captured with the confocal microscope DEclipse C1 (Nikon) mounted on a light microscope Eclipse TE2000-E (Nikon) and analysed using Image Pro Premier software (Media Cybernetics, Inc. MD 20910 USA). All confocal microscope parameters were maintained stable for each acquisition. For each image we obtained the percentage of labelled compared to total tissue area (%pixel 2 ); COL6A5 intensity was standardized on the intensity of laminin V, and the ratio between the percentage of green and red areas was calculated.
Results
Whole exome sequencing
The variant filtering pipeline applied for Families 1 and 3 disclosed several candidate variants with COL6A5 as a common segregating candidate gene (Table 1 ). The final list of gene variants in Family 3 included the variant 2215A 4 G, p.Ile739Val in SCN9A (rs182650126), which was previously reported (Devigili et al., 2014) . Following the results of these family-based studies, the whole-exome sequencing data of the proband of Family 2 were inspected for variants in all of the obtained candidate genes. This analysis revealed COL6A5 as the only gene shared between all the three families according to an autosomal dominant model (Fig. 1) . In particular, all affected members of Family 1 and the proband of Family 2 with itch showed the variant c.6814G 4 T, (rs115375867), whereas affected members of Family 3 carried the variant c.6486G 4 C, (rs368345789). The segregation analysis of the c.6814G 4 T variant in all available Family 2 members confirmed the association with itch while excluded the association with JHS/EDS-HT. Indeed, the variant was identified in the proband's daughter affected with JHS/EDS-HT and complaining of itch, but was absent from the genome of the proband's niece with JHS/EDS-HT (Patient III:1) as well as in her healthy daughter (Patient III:3), both not reporting chronic itch (Fig. 1) .
The c.6814G 4 T transversion leads to a premature stop codon at position 2272 (p.Glu2272 The c.6486G 4 C transition found in Family 3 leads to an amino acid change at position 2162 (p.Arg2162Ser). Arg2162 is highly conserved [Genomic Evolutionary Rate Profiling GERP + + = 2.26] (Fig. 1) , and the missense substitution is predicted as pathogenic by PolyPhen-2 and SIFT. The variant has a very low frequency in ExAC (MAF = 3.2
À5
) and was absent in 5036 exomes from the Radboudumc/MUMC Maastricht database, 235 exomes from the TwinsUK database and in 1033 controls from the Italian Reference Genome v1.
The two COL6A5 variants p.Glu2272 * and p.Arg2162Ser were sequenced in a cohort of 77 patients with idiopathic and diabetic neuropathy and in 167 JHS/EDS-HT patients without itch. Among them, one English 64-year-old female patient with type 1 diabetes screened positive for the p.Glu2272 * mutation. This patient had good glycaemic control (HbA1c 51 mmol/mol), mild painless neuropathy (sural sensory action potential amplitude 4.3 mV, normal value 46 mV) with normal IENFD (15.3/mm; 5th percentile 4.3/mm), and complained of chronic itch in the lower limbs for about 10 years.
Functional assays
Null-allele test on cDNA from proband's fibroblasts of Families 1 and 2 carrying the p.Glu2272 * mutation demonstrated the expression of wild-type allele only due to activation of nonsense mediated RNA decay ( Fig. 2A) . Western blot and immunofluorescence analyses confirmed the functional haploinsufficiency. Western blot demonstrated reduced steady-state levels of COL6A5 in patients' cells compared to controls (Fig. 2B) . The $50% amount of the protein synthesized by the cells is not sufficient for its organization in the extracellular matrix, thus resulting in a 21-37-fold decrease of COL6A5 signal in patients' cells compared to control fibroblasts ( Fig. 2C and Table 2 ). COL6A5 expression was also reduced in the papillary dermis and around the dermal vessels of patients compared to controls (Fig. 3) . Epidermis, dermal connective tissue and skin adnexa showed normal morphology (Fig. 4) .
Discussion
Pain and itch are different responses to stimuli activating common pathways modulated by excitatory and inhibitory neurons in the dorsal horns of the spinal cord (Dhand and Aminoff, 2014; LaMotte et al., 2014) , among which glycinergic neurons likely play a key role (Foster et al., 2015) . Under certain conditions, not well understood, itch can prevail over pain as a consequence of an altered balance of activation among specific groups of neurons (Ma, 2012) .
Our findings indicate an association of COL6A5 with chronic itch, which is common in the general population (Weisshaar and Dalgard, 2009; Stander et al., 2010) and shows an incidence that increases with age (Matterne et al., 2011) . Two rare variants co-segregated with a chronic itch phenotype in eight patients from three kindred and in one sporadic patient. The high and probably underestimated prevalence of chronic itch among the general population could somehow reconcile the allele frequency of the p.Glu2272 * nonsense variant, which is of $1% in ExAC, as well as the presence of other loss-of-function variants (including several nonsense) that are reported in ExAC. Further chronic itch families and patients are needed to identify additional COL6A5 variants as well as functional data connecting impaired COL6A5 function to the itch phenotype. Previous studies have found a linkage between COL6A5 variants, osteopenia, respiratory abnormalities and giant cell arteritis (Wang et al., 2016) . However, the preliminary association with atopic dermatitis (Soderhall et al., 2007) was not subsequently confirmed (Esparza-Gordillo et al., 2009; Naumann et al., 2011) .
COL6A5 (formerly known as COL29A1) is a member of the collagen superfamily of proteins. COL6A5 is present in epithelial tissues including the lungs and gastrointestinal tract (Fitzgerald et al., 2008) , but shows the highest expression below the dermal-epidermal junction and around the vessels of the reticular dermis (Sabatelli et al., 2011) , where patients carrying the nonsense mutation showed reduced expression.
Family 2 was also affected by JHS/EDS-HT, a heritable soft connective tissue disorder in which pain and reduced IENFD are common (Voermans et al., 2010) , whereas itch is not a typical symptom. In this family, the COL6A5 variant co-segregated with itch but not with JHS/EDS-HT, a fact that strengthens the correlation with itch. Moreover, the same mutation has been found in the affected members of Family 1, who are not diagnosed with JHS/EDS-HT, and in one sporadic patient with painless diabetic neuropathy and itch.
We have previously described the presence of the p.Ile739Val variant in SCN9A in Family 3 (Devigili et al., 2014) . This variant was first reported in three unrelated sporadic patients with small fibre neuropathy and severe dysautonomia (Faber et al., 2012) . Notably, it was demonstrated that it caused DRG neuron hyperexcitability and sympathetic cervical ganglion autonomic neuron hypoexcitability, explaining both pain and autonomic dysfunction in the patients . However, itch has never been reported in association with sodium channel mutations (Black and Waxman, 2013; Waxman, 2013) . Therefore, we followed-up the kindred over time and undertook more detailed genetic analysis. Remarkably, we first confirmed the correlation between cell electrophysiological recording and a dysautonomia phenotype for the p.Ile739Val variant in SCN9A (Han  et al., 2012) . Indeed, the proband's mother developed overt cardiovascular dysautonomia and sympathetic cholinergic impairment after 3 years follow-up, evidenced by symptoms and impaired sympathetic skin response and cardiovascular autonomic function testing, which were normal at the initial evaluation (Devigili et al., 2014) . However, at the onset of the paroxysmal itch symptoms, this patient had undergone cardiac ablation for an arrhythmia of unknown origin, which we could a posteriori speculate to have been facilitated by a hidden dysautonomia. The current lack of dysautonomic disturbances in the daughters affected by itch could be explained by their younger age. Whether the p.Ile739Val also contributes to itch because it causes hyperexcitability of DRG neurons remains to be confirmed. However, the strong co-segregation in Family 3 of the missense variant in COL6A5, along with the discovery of the Table 2 . Scale bar = 10 mm). Family 3, Patients II:2 and I:2) showed reduced epidermal innervation. The involvement of unmyelinated and thinly myelinated nerve fibres conveying thermosensation and nociception is considered central to the development of itch (Yosipovitch and Bernhard, 2013) and itch can dominate the clinical picture in $4.5% of small fibre neuropathy patients (Devigili et al., 2008) . This percentage can rise up to 68% if itch is recorded in the wider spectrum of small fibre neuropathy painful symptoms (Brenaut et al., 2015) . None of our patients showed the typical length-dependent distribution of symptoms occurring in small fibre neuropathy. Three itch patients carrying COL6A5 variants (Family 1, Patient I:2; Family 3, Patient II:4; the unrelated sporadic diabetic neuropathy patient) did not have small fibre neuropathy.
Moreover, we have recently demonstrated that small fibre neuropathy is part of the JHS/EDS phenotype (Cazzato et al., 2016) . Overall, these findings make the association between small nerve fibres impairment and itch weak, at least in our cohort of patients. Finally, in all patients gabapentinoids (e.g. gabapentin and pregabalin) produced satisfactory relief from itch. The efficacy of gabapentin in treating itch associated with neurogenic or kidney diseases, or of unknown origin, has been confirmed in recent meta-analyses (Matsuda et al., 2016; Pongcharoen and Fleischer, 2016) . Gabapentinoids, one of the first-line treatments for neuropathic pain (Attal et al., 2010) , bind to the 2 subunit of voltage-gated calcium channels, but their mechanisms of action in neuropathic pain are only partly elucidated and those underlying the efficacy in itch remain unknown (Rose and Kam, 2002) . Similarly, there are no pharmacological data that allow raising hypotheses to correlate the effect of gabapentinoids observed in our patients and COL6A5. Thus, our findings confirm the positive effect of this class of drugs on itch, but further studies are needed to provide hints on possible mechanisms. Besides the primary antiallodynic effect, gabapentinoids have also been shown to inhibit the ectopic discharge activity from injured peripheral nerves (Pan et al., 1999) to whose pathophysiology sodium channels are known to contribute (Dib-Hajj et al., 2010) . Recent evidence that a monoclonal antibody targeting Na v 1.7 could suppress both histaminergic and non-histaminergic chloroquine-induced itch by inhibiting tetrodotoxinsensitive sodium currents and action potentials in DRG nociceptors may also suggest an involvement of sodium channels in the management of itch (Lee et al., 2014) .
